 SAN DIEGO, May 17, 2021 PRNewswire -- Evofem Biosciences, Inc., NASDAQ: EVFM today announced that new research on its investigational drug EVO100 for the prevention of chlamydia and gonorrhea in women will be highlighted in a poster presentation at the annual meeting of the Professional Society for Health Economics and Outcomes Research, Virtual ISPOR 2021, which will be held May 17 to 20, 2021. Abstract: 108785 Title: Assessing the Understandability and Importance of Patient Reported Outcomes Impacting Adherence and Outcomes of a Non-Hormonal Vaginal Microbicide to Protect Against Chlamydia Trachomatis CT and Neisseria Gonorrhoeae GC Authors: Robert Morlock, PhD; Lalitha Aiyer, MD, MS, MBA, FAIHM; Kelly Culwell, MD, MPH, FACOG; Brandon Howard, PhD Date: Tuesday, May 18, 2021 Qualitative research was conducted among 21 women with previous experience with EVO100. 